Udai S. Kammula

30.1k total citations · 14 hit papers
89 papers, 18.2k citations indexed

About

Udai S. Kammula is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Udai S. Kammula has authored 89 papers receiving a total of 18.2k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 59 papers in Immunology and 21 papers in Molecular Biology. Recurrent topics in Udai S. Kammula's work include Immunotherapy and Immune Responses (51 papers), CAR-T cell therapy research (42 papers) and Cancer Immunotherapy and Biomarkers (37 papers). Udai S. Kammula is often cited by papers focused on Immunotherapy and Immune Responses (51 papers), CAR-T cell therapy research (42 papers) and Cancer Immunotherapy and Biomarkers (37 papers). Udai S. Kammula collaborates with scholars based in United States, Malaysia and Germany. Udai S. Kammula's co-authors include Steven A. Rosenberg, Richard M. Sherry, Marybeth S. Hughes, James Chih‐Hsin Yang, Richard E. Royal, Nicholas P. Restifo, Mark E. Dudley, Suzanne L. Topalian, Donald E. White and Giao Q. Phan and has published in prestigious journals such as Science, Nature Medicine and Nature Communications.

In The Last Decade

Udai S. Kammula

89 papers receiving 17.8k citations

Hit Papers

Cancer Regression in Patients After Transfer of Genetical... 2005 2026 2012 2019 2006 2011 2011 2008 2010 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
    2006 2.0k citations Richard A. Morgan, Mark E. Dudley et al. Science profile →
  2. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
    2011 1.6k citations Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research profile →
  3. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
    2011 1.1k citations Mark E. Dudley, Steven A. Feldman et al. profile →
  4. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
    2008 1.0k citations Mark E. Dudley, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
  5. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
    2010 954 citations Richard E. Royal, Catherine Lévy et al. profile →
  6. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
    2010 791 citations James C. Yang, Russell C. Langan et al. profile →
  7. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
    2005 771 citations Giao Q. Phan, Martha Quezado et al. Journal of Clinical Oncology profile →
  8. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment
    2006 662 citations Udai S. Kammula et al. profile →
  9. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4
    2006 646 citations Joseph Blansfield, Khoi Q. Tran et al. Journal of Clinical Oncology profile →
  10. Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans
    2014 645 citations Giao Q. Phan, Udai S. Kammula et al. profile →
  11. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
    2014 585 citations Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research profile →
  12. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
    2007 537 citations James Chih‐Hsin Yang, Marybeth S. Hughes et al. profile →
  13. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
    2007 519 citations Jacob A. Klapper, Franz O. Smith et al. Clinical Cancer Research profile →
  14. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
    2015 506 citations Sanja Stevanović, Lindsey M. Draper et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Udai S. Kammula United States 46 14.0k 10.2k 4.2k 2.7k 1.3k 89 18.2k
John R. Wunderlich United States 54 15.8k 1.1× 14.8k 1.4× 4.8k 1.1× 3.4k 1.3× 849 0.6× 121 21.1k
Richard M. Sherry United States 51 18.5k 1.3× 13.8k 1.3× 6.1k 1.4× 3.8k 1.4× 2.8k 2.1× 97 25.0k
Marybeth S. Hughes United States 31 11.4k 0.8× 7.7k 0.8× 2.9k 0.7× 2.4k 0.9× 1.1k 0.8× 85 13.7k
Taku Okazaki Japan 45 12.4k 0.9× 11.9k 1.2× 2.8k 0.7× 847 0.3× 1.8k 1.3× 70 20.0k
Robert H. Vonderheide United States 74 15.2k 1.1× 14.2k 1.4× 6.9k 1.6× 1.1k 0.4× 2.4k 1.8× 224 25.0k
Maurilio Ponzoni Italy 65 6.6k 0.5× 3.8k 0.4× 4.7k 1.1× 2.3k 0.9× 973 0.7× 296 16.6k
Zhiya Yu United States 54 8.8k 0.6× 8.6k 0.8× 3.9k 0.9× 2.4k 0.9× 388 0.3× 95 14.2k
Phillip K. Darcy Australia 65 9.2k 0.7× 7.5k 0.7× 3.9k 0.9× 1.7k 0.6× 876 0.7× 194 14.2k
Luca Gattinoni United States 55 10.5k 0.8× 10.8k 1.1× 4.1k 1.0× 2.5k 0.9× 383 0.3× 101 16.1k
Patrick Hwu United States 59 9.4k 0.7× 10.0k 1.0× 4.4k 1.0× 1.6k 0.6× 1.6k 1.2× 220 15.8k

Countries citing papers authored by Udai S. Kammula

Since Specialization
Citations

This map shows the geographic impact of Udai S. Kammula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udai S. Kammula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udai S. Kammula more than expected).

Fields of papers citing papers by Udai S. Kammula

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udai S. Kammula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udai S. Kammula. The network helps show where Udai S. Kammula may publish in the future.

Co-authorship network of co-authors of Udai S. Kammula

This figure shows the co-authorship network connecting the top 25 collaborators of Udai S. Kammula. A scholar is included among the top collaborators of Udai S. Kammula based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Udai S. Kammula. Udai S. Kammula is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kammula, Udai S., et al.. (2025). Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma. Immunotherapy. 17(4). 283–291. 2 indexed citations
2.
Guo, Weiwei, Ghanshyam S. Yadav, Zehua Wang, et al.. (2022). Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response. Science Advances. 8(49). eadd0005–eadd0005. 10 indexed citations
3.
Monaco, Sara E., et al.. (2019). Cytologic Evaluation of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. American Journal of Clinical Pathology. 153(4). 513–523. 1 indexed citations
4.
Stevanović, Sanja, Sarah R. Helman, John R. Wunderlich, et al.. (2018). A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers. Clinical Cancer Research. 25(5). 1486–1493. 204 indexed citations
5.
Rothermel, Luke D., Arvind Sabesan, Daniel J. Stephens, et al.. (2015). Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clinical Cancer Research. 22(9). 2237–2249. 64 indexed citations
6.
Zhang, Ling, Richard A. Morgan, Joal D. Beane, et al.. (2015). Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research. 21(10). 2278–2288. 332 indexed citations
7.
Chandran, Smita S., Biman C. Paria, Abhishek K. Srivastava, et al.. (2015). Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc. Cancer Research. 75(16). 3216–3226. 23 indexed citations
8.
Stevanović, Sanja, Lindsey M. Draper, Michelle M. Langhan, et al.. (2015). Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology. 33(14). 1543–1550. 506 indexed citations breakdown →
9.
Chandran, Smita S., Biman C. Paria, Abhishek K. Srivastava, et al.. (2014). Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. Clinical Cancer Research. 21(3). 534–543. 39 indexed citations
10.
Bartlett, Edmund K., Patricia Fetsch, Armando Filie, et al.. (2014). Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration. Clinical Cancer Research. 20(10). 2607–2616. 21 indexed citations
11.
Robbins, Paul F., Sadik H. Kassim, Thai L.N. Tran, et al.. (2014). A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research. 21(5). 1019–1027. 585 indexed citations breakdown →
12.
Prieto, Peter A., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2012). CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. Clinical Cancer Research. 18(7). 2039–2047. 369 indexed citations
13.
Rosenberg, Steven A., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2011). Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research. 17(13). 4550–4557. 1603 indexed citations breakdown →
14.
Dudley, Mark E., Colin Gross, Michelle M. Langhan, et al.. (2010). CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clinical Cancer Research. 16(24). 6122–6131. 245 indexed citations
15.
Dudley, Mark E., James Chih‐Hsin Yang, Richard M. Sherry, et al.. (2008). Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology. 26(32). 5233–5239. 1017 indexed citations breakdown →
16.
Blansfield, Joseph, Khoi Q. Tran, Andrew L. Feldman, et al.. (2006). Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology. 24(15). 2283–2289. 646 indexed citations breakdown →
17.
Morgan, Richard A., Mark E. Dudley, John R. Wunderlich, et al.. (2006). Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science. 314(5796). 126–129. 1961 indexed citations breakdown →
18.
Ohnmacht, Galen A., Ena Wang, Simone Mocellin, et al.. (2001). Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination. The Journal of Immunology. 167(3). 1809–1820. 69 indexed citations
19.
Kammula, Udai S., Donald E. White, & Steven A. Rosenberg. (1998). Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83(4). 797–805. 152 indexed citations
20.
Kammula, Udai S., Donald E. White, & Steven A. Rosenberg. (1998). Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer. Cancer. 83(4). 797–805. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John R. Wunderlich Breakdown of academic impact, for papers by Richard M. Sherry Breakdown of academic impact, for papers by Marybeth S. Hughes Breakdown of academic impact, for papers by Taku Okazaki Breakdown of academic impact, for papers by Robert H. Vonderheide Breakdown of academic impact, for papers by Maurilio Ponzoni Breakdown of academic impact, for papers by Zhiya Yu Breakdown of academic impact, for papers by Phillip K. Darcy Breakdown of academic impact, for papers by Luca Gattinoni Breakdown of academic impact, for papers by Patrick Hwu
Rankless by CCL
2026